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Abstract
Background: Survivin is an inhibitor of apoptosis and its over expression is associated with poor prognosis in several
malignancies. While several studies have analyzed survivin expression in esophageal squamous cell carcinoma, few have
focused on esophageal adenocarcinoma (EAC) and/or cancer-adjacent squamous epithelium (CASE). The purpose of this
study was 1) to determine the degree of survivin up regulation in samples of EAC and CASE, 2) to evaluate if survivin
expression in EAC and CASE correlates with recurrence and/or death, and 3) to examine the effect of survivin inhibition on
apoptosis in EAC cells.
Methods: Fresh frozen samples of EAC and CASE from the same patient were used for qRT-PCR and Western blot analysis,
and formalin-fixed, paraffin-embedded tissue was used for immunohistochemistry. EAC cell lines, OE19 and OE33, were
transfected with small interfering RNAs (siRNAs) to knockdown survivin expression. This was confirmed by qRT-PCR for
survivin expression and Western blot analysis of cleaved PARP, cleaved caspase 3 and survivin. Survivin expression data was
correlated with clinical outcome.
Results: Survivin expression was significantly higher in EAC tumor samples compared to the CASE from the same patient.
Patients with high expression of survivin in EAC tumor had an increased risk of death. Survivin expression was also noted in
CASE and correlated with increased risk of distant recurrence. Cell line evaluation demonstrated that inhibition of survivin
resulted in an increase in apoptosis.
Conclusion: Higher expression of survivin in tumor tissue was associated with increased risk of death; while survivin
expression in CASE was a superior predictor of recurrence. Inhibition of survivin in EAC cell lines further showed increased
apoptosis, supporting the potential benefits of therapeutic strategies targeted to this marker.
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Introduction
Esophageal cancer is currently the eighth most common cancer
worldwide; with esophageal adenocarcinoma (EAC) accounting
for 50% of esophageal cancer cases [1–5]. The five-year survival
for esophageal cancer is less than 20% and its incidence has
increased by almost three fold in the western hemisphere in the
past 20 years [6,7]. Most EAC patients are diagnosed with
advanced stage disease and have poor long-term survival rates
with the currently employed chemotherapeutic agents [5,8,9]. The
efficacy of current regimens has reached a plateau and further
intensification of cytotoxic agents or radiation dose escalation has
been shown to be associated with significant adverse side effects.
Consequently, the need for the development of effective targeted
therapies aimed at treating specific mechanisms of carcinogenesis
are required in order to improve survival [2–4,10,11].
Survivin, also known as Baculoviral Inhibitor of apoptosis
Repeat-Containing 5 or BIRC5, is an inhibitor of apoptosis or
programmed cell death [10–13]. The mechanism of action
through the intrinsic pathway is as follows: survivin binds to and
inhibits caspase 9, causing deactivation of the apoptotic pathway;
procaspase 3 is not cleaved and thus does not cleave PARP (Poly
ADP-ribose polymerase); as a result, PARP remains active and
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continues with DNA repair, resulting in the inhibition of apoptosis
(Figure 1) [8,10,11,13,14]. Ordinarily survivin is only found
during embryonic and fetal development as a means to regulate
proper cell division and growth and is undetectable in most
terminally differentiated normal tissues [15]. Some normal adult
tissues with persistent survivin expression include hematopoietic
stem cells [16], thymocytes [17], melanocytes [18], gastric mucosa
[19] and colonic epithelium [19]. Studies have reported increased
expression of survivin in a number of cancers including breast,
lung, melanoma, leukemia, lymphoma, colon, pancreas, and etc.
[15]. Evidence also supports over expression of survivin in
esophageal squamous cell carcinoma and its association with a
poor prognosis [3,4,8,10,11,20]. Because survivin is not expressed
in the majority of healthy tissues, it represents an ideal target for
the development of novel cancer agents [3,4,8,10,11,13,20,21]. In
fact agents targeting survivin are currently in phase I and phase II
clinical trials in patients with advanced cancer where methods of
inhibition include antisense oligonucleotides (ASOs), transcrip-
tional repressors, and immunotherapy [10,14,22]. Some of these
agents have demonstrated promising initial results, however none
have improved overall survival [3,4,7,10,11,14,22–24].
Although there have been many reports analyzing the role of
survivin in esophageal squamous cell carcinoma (SCC), very few
studies have addressed its role in esophageal adenocarcinoma
(EAC) [3,4,7–9,21,25,26]. In addition expression of this anti-
apoptotic gene in the cancer-adjacent squamous epithelium
(CASE) has not been studied. The purpose of our study, therefore,
was 1) to determine the degree of survivin up regulation in samples
of EAC patients and CASE, 2) to evaluate recurrence and survival
with survivin expression in EAC and CASE tissue, and 3) to
examine the effect of survivin inhibition on apoptosis in EAC cell
lines.
Materials and Methods
Ethics Statement
The study was performed after obtaining approval from
University of Pittsburgh Institutional Review Board. Samples
were taken from the UPMC Cancer Center - Esophageal Cancer
Risk Registry, University of Pittsburgh IRB Study Number 98–
122 with URL: http://www.upmccancercenter.com/trials/
trialDisplay.cfm?id = 2277&type=D. As a part of the study, all
patient samples were obtained with full written consent.
Cell Lines
The EAC cell lines OE19 (JROECL19) and OE33
(JROECL33) were obtained through Sigma-Alderich (St. Louis,
MO). They were both maintained in Roswell Park Memorial
Institute (RPMI) 1640 cell growth media (Life Technologies,
Carlsbad, CA, 21870076), supplemented with 10% Fetal bovine
serum (FBS) (Life Technologies, Carlsbad, CA, 26140079), 1% L-
Glutamine (Life Technologies, Carlsbad, CA, 25030081), 1%
Penicillin-Streptomycin (Life Technologies, Carlsbad, CA,
15070063). All cells were stored in 25 cm2 flasks and incubated
at 37uC with 5% CO2 humidified air. Trypsin-EDTA (Life
Technologies, Carlsbad, CA, 25200072) was used to harvest the
cells from their flask and prepare a single cell suspension for
Western blot analysis and Reverse Transcription – Polymerase
Chain Reaction (RT-PCR).
siRNA Transfection
OE33 and OE19 were seeded in a 6-well plate at a density of
46105 24 hours before transfection. Cells were either transfected
with small interfering RNAs (siRNAs) or untreated. The siRNA
categories utilized included survivin specific siRNA, or negative
control (scramble) (Dharmacon, Lafayette, CO, D-001810-10-05).
Each siRNA solution was diluted from the 100 mM stock to 5 mM
in RNase-free H2O, then diluted to 0.25 mM in Opti-MEM (Life
Technologies, Carlsbad, CA, 31985062). Simultaneously, 2 mL of
transfection reagent 4 (Dharmacon, Lafayette, CO, T-2004) per
reaction was diluted with 98 mL of Opti-MEM. The solutions were
separately incubated for 5 minutes at room temperature, mixed
together, and incubated for another 20 minutes at room
temperature. The final siRNA solution was diluted to 1 mL per
reaction with Opti-MEM for a final concentration of 25 gM. The
cells were incubated at 37uC in 5% CO2 humidified air, with a
RPMI media change after 24 hours. Whole cell lysate was
collected at 48 hours for RNA analysis or 72 hours for protein
analysis.
Patients and Tissue Preparation
The study was performed after obtaining approval from
University of Pittsburgh Institutional Review Board. Patients
who underwent esophagectomy for localized esophageal adeno-
carcinoma from beginning of 2008 to end of 2010 were included
in the study. Forty-seven samples were screened and after
excluding squamous cell carcinoma, adenosquamous cancer, and
tissue blocks with less than 70% tumor, a total of 37 patient
samples were analyzed for this study. Clinical data including age,
sex, ethnicity, clinical stage, vital status, smoking history, overall
survival, and time to recurrence was obtained from the
Department of Cardiothoracic Surgery clinical database. To
ensure patient confidentiality, an honest broker system was utilized
to provide de-identified clinical dataset linked to tissue samples
[27]. Fresh frozen tissue embedded in OCT was used for
quantitative reverse transcription-polymerase chain reaction
(qRT-PCR) and Western blot analysis. Formalin-fixed, paraffin-
embedded (FFPE) tissue was used for immunohistochemistry.
Western Blot Analysis
Protein was collected from each cell line treatment group by
adding lysis buffer (RIPA buffer containing 0.1% protease
inhibitor cocktail mix, 0.1% Halt phosphatase inhibitor cocktail
mix and 1% PMSF) and using a cell lifter. The solution was
Figure 1. Survivin inhibition pathway. Survivin binds to and
inhibits caspase 9, caspase 9 is unable to cleave caspase 3, caspase 3 is
unable to cleave PARP, PARP promotes DNA repair and does not induce
apoptosis.
doi:10.1371/journal.pone.0078343.g001
Survivin Expression and Esophageal Adenocarcinoma
PLOS ONE | www.plosone.org 2 November 2013 | Volume 8 | Issue 11 | e78343
rotated for one hour at 4uC to fully lyse the cells, then spun at
12,000 g at 4uC for 20 minutes to separate the protein. The
supernatant containing the protein was collected and quantified
using BCA Pierce Assay (Thermofisher, Rockford, IL, 23227).
Thirty-five mg of protein from each sample was denatured and
resolved by 4–20% SDS-PAGE gradient gel (Bio-Rad, Hercules,
CA, 161–1159), then electroblotted to a Immobilon-P PVDF
nitrocellulose membrane (Millipore Corporation, Billerica MA,
IPVH08100). The membrane was blocked in 5% non-fat dried
milk in TBS-T at room temperature for one hour. The antibody of
interest was incubated with the membrane at 4uC overnight,
followed by 1.5 hour incubation at room temperature in the
corresponding horseradish peroxidase-conjugated secondary anti-
body (Cell Signal, Boston MA, 7074 or 7076, 1:3,000) Survivin
antibody (Santa Cruz Biotechnology, Dallas, Tx, sc-47750) was
used at 1:200, caspase-3 (Cell Signal, Boston, MA, 9665) at
1:1,000, cleaved-PARP (Cell Signal, Boston, MA, 9546) at 1:2,000
and b-actin (Sigma-Aldrich, St. Louis, MO, A1978) at 1:30,000
was used as a loading control. Signals were developed using a
chemiluminescence reagent (Fisher Scientific, Pittsburgh, PA,
509049324).
Quantitative Reverse Transcription – Polymerase Chain
Reaction (qRT-PCR)
Total RNA was purified from cell lines using the RNeasy Micro
Kit (Qiagen, Valencia, CA, 74004). Briefly, pellets containing
16106 cells were vortexed in RLT lysis buffer and RNA was
extracted following manufacturer’s protocol using an elution
volume of 14 ul. Using an ND-2000 spectrophotometer (Nano-
drop Technologies, Inc, Wilmington, DE), the quality and
quantity of RNA was assessed by OD260/280. Complementary
DNA (cDNA) was reverse transcribed from 3 ug total RNA using
RNA to cDNA ecodry premix in a total volume of 20 ul
(Clontech, Mountain View, CA, 639547) according to the
manufacturer’s protocol. The reaction conditions were 42uC for
60 minutes, followed by 70uC for 10 minutes using ABI Prism
7900HT PCR thermocycler (Applied Biosystems, Carlsbad, CA).
PCR was performed in a total volume of 20 ul using 600 ng
cDNA, 16Taqman PCR universal mastermix (Invitrogen, Grand
Island, NY, 4304437), and 16 Survivin or GAPDH primer
(Applied Biosystems, Carlsbad, CA hs03043576_m1 and
hs99999905_m1) for each reaction. The cycling parameters were:
one cycle of 95uC for ten minutes, followed by 45 cycles of 95uC
for 15 seconds, and 60uC for one minute on a StepOne Plus
system (Applied Biosystems, Carlsbad, CA). All reactions were run
in technical duplicates.
Figure 2. Quantitative real time polymerase chain reaction (qRT-PCR) of patient survivin levels. A: qRT-PCR was performed to compare
survivin expression between tumor and adjacent squamous epithelial tissue. B: On average, tumor samples showed 36greater survivin expression
than paired adjacent tissue.
doi:10.1371/journal.pone.0078343.g002
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Figure 3. Immunohistochemistry of survivin in human tissue. Survivin expression was evaluated through IHC staining, tumor tissue and
adjacent squamous epithelium showed presence of staining indicative of survivin expression. Arrows represent positive staining.
doi:10.1371/journal.pone.0078343.g003
Figure 4. A: Reverse transcriptase polymerase chain reaction of siRNA inhibition of survivin in EAC cell line. OE19 and OE33 EAC cell
lines were transfected with siRNA and survivin expression was analyzed between control and transfected cell lines. Both cell lines transfected with
siRNA showed clear inhibition and downregulation of survivin expression. B: Western blot of siRNA inhibition of survivin in EAC cell line.
siRNA was incubated with OE19 and OE33 cell lines to inhibit survivin expression. b-Actin was used as a loading control. Survivin was downregulated,
while downstream apoptotic proteins cleaved caspase 3 and cleaved PARP were upregulated. The upregulation of downstream apoptotic proteins
indicates apoptosis occurs through incubation with siRNA.
doi:10.1371/journal.pone.0078343.g004
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Extraction of total RNA from fresh frozen tissue was done using
the Qiagen RNeasy Mini kit (Qiagen, Valencia, CA 74104).
Briefly, 10 mm OCT sections were cut into RLT buffer, lysed
using a 20 gauge blunt end needle and RNA was extracted
following manufacturer’s instructions using an elution volume of
50 ul. qRT-PCR was performed with the One-step qRT-PCR Kit
(Life Technologies, Carlsbad, CA 4310299) according to manu-
facturer’s instructions in a total volume of 20 ul using 2 ul of tissue
lysate and 16Survivin or 16GAPDH primer (Life Technologies,
Carlsbad, CA hs03043576_m1 and hs99999905_m1) for each
reaction. The cycle conditions used were: 1 cycle of 50uC for 30
minutes, 95uC for 2 minutes, and 50 cycles of 95uC for 15 seconds,
60uC for 45 seconds using ABI Prism 7700 Sequence Detection
System (Applied Biosystems, Carlsbad, CA). All reactions were run
in technical triplicates. Amplification plots for both sample
categories, cell lines and fresh frozen tissues were examined with
StepOne software, provided with the StepOne Plus system, to
determine the cycle threshold (CT). GAPDH was used for
normalization of expression data. The 22DCT method was used
to determine survivin fold expression in tumor tissue and CASE.
Immunohistochemistry
FFPE sections were immunostained to show survivin expression
in EAC tumor and paired squamous epithelial samples. Reactive
human tonsil and non-immune serum were run in parallel as
positive and negative controls, respectively. Tissue samples were
cut at 4 mm onto charged slides and deparaffinized. The slides
were immersed in 0.01% Triton X-100 for ten minutes at room
temperature, rinsed in tap H2O, then submerged in 10 mM citrate
buffer, pH 6.0 at 95uC for 20 minutes for antigen retrieval.
Blocking occurred by 3% H2O2 followed by a tap water wash.
After three washes of 16 Tris-buffered saline with 0.001%
Tween20 (TBS-T), slides were further blocked in 2.5% normal
horse serum (Vector Laboratories, Burlingame, CA, MP7401).
The survivin primary antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, sc47750) was applied at 1:50, overnight at 4uC. Slides
were washed three times in TBS-T, then incubated in ImmPress
anti-rabbit reagent (Vector Laboratories, Burlingame, CA,
MP7401) for 30 minutes to aid in survivin expression detection.
Again, the slides were washed three times in TBS-T, and
developed using ImmPact DAB (Vector Laboratories, Burlingame,
CA, SK4105).
Statistical Analysis
Statistical analyses were performed using SPSS software (IBM,
Armonk, NY, Version 20). A p-value ,0.05 was considered
statistically significant. Within each tissue sample, mean values of
Survivin mRNA expression levels (determined by 22DCT method)
were evaluated in both EAC tumor tissue (tumor survivin level)
and CASE tissue samples (normal survivin level). Student’s t test
was used to compare mean tumor and normal survivin levels.
Receiver operating characteristic (ROC) analysis was used to
determine if survivin levels could be used to define high and low
risk groups for recurrence; the high risk/low risk thresholds
established in the ROC analyses were used to categorize patients
as high risk/low risk for both CASE tissue survivin levels and EAC
tissue survivin levels. Separate ROC analyses were conducted
predicting recurrence from CASE tissue survivin levels and from
EAC tissue survivin levels. In both cases visual inspection of the
produced graphical figures were used in conjunction with listed
Survivin score cut points with corresponding sensitivity and (1
minus) specificity in order to determine optimum thresholds to
define high and low risk groups.
Regarding the ROC procedure for threshold determination, we
used the standard method of visually inspecting the curve to
determine that point closest to the upper-left corner of the ROC
figure, along with inspection of corresponding sensitivity and
specificity values along available values. This provided a means of
determining which value provided the best balance between
sensitivity and specificity. Upon inspection of the ROC figures,
this inspection was relatively straightforward for CASE, however
was somewhat less straightforward for tumor cell levels. In that
case, a value was chosen that emphasized sensitivity at the expense
of specificity, as false negatives were judged to be more dangerous
than were false positives. This relied more heavily on the
Table 1. Characteristics of the 37 patients included in the
study.
Patients N=37
Age 62.7 (range, 44–90)
Sex, M:F 30:7
Stage Stage I, 6 (16.2%)
Stage II, 13 (35.2%)
Stage III, 18 (48.6%)
Peri-operative therapy Neoadjuvant therapy, 7 (19%)
Adjuvant chemotherapy, 18 (48.6%)
No peri-operative therapy, 12 (32.4%)
Recurrence (N = 13) Stage I, 0 (0%)
Stage II, 3 (23%)
Stage III, 10 (77%)
Follow-up period (month) 12 months (range, 0.4–30.3)
doi:10.1371/journal.pone.0078343.t001
Table 2. Stage of Tumor by Survivin Expression Level.
Adjacent Survivin Epithelium Expression Tumor Survivin Expression
Low Risk High Risk Low expression High expression
Stage I 5 1 0 6
Stage IIa 2 2 1 3
Stage IIb 6 3 4 5
Stage III 10 8 5 13
Total 37 37
doi:10.1371/journal.pone.0078343.t002
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calculated sensitivity/specificity values as there was a non-
significant AUC (area under curve) and accordingly no visually
apparent cut point.
Kaplan-Meier curve was generated to determine survival based
on high and low risk recurrence groups. A Mantel-Cox Log Rank
Test was conducted in order to compare overall survival between
risk groups. A Cox proportional hazards model was used to assess
the effectiveness of survivin level within both CASE and EAC
tissue samples in predicting mortality.
Results
Overexpression of survivin in EAC cell lines, human
tumor and CASE tissue
Survivin mRNA expression was significantly higher in tumor
samples when compared to CASE tissue samples on qRT-PCR
analysis (Figure 2A). On average, tumor samples demonstrated
levels of survivin expression 36 greater than that of CASE tissue
(p,0.00001. Figure 2B). Immunohistochemistry (Figure 3) and
Western Blot analysis (data not shown) also confirmed survivin
expression in both EAC tumor as well as CASE.
Inhibition of survivin in EAC cell lines resulted in
increased apoptosis
siRNA targeted to survivin resulted in decreased expression of
survivin in OE19 and OE33 cell lines compared to controls on
qRT-PCR (Figure 4A). Similarly, siRNA incubation resulted in
downregulation of survivin expression in both cell lines on Western
Blot analysis. The decrease in survivin expression resulted in
upregulation of the downstream apoptotic protein, cleaved PARP.
Cleaved caspase 3 was consumed through the reaction with
PARP, resulting in upregulation of cleaved PARP (Figure 4B).
Table 3. Chemotherapy by Survivin Expression Level.
Adjacent Survivin Epithelium Expression Tumor Survivin Expression
Low Risk High Risk Low expression High expression
Neo-Adjuvant 0 7* 0 7
Adjuvant 12 6 8 10
No Treatment 11 1 2 10
Total 37 37
*2 patients received concurrent chemoradiation.
doi:10.1371/journal.pone.0078343.t003
Figure 5. ROC analysis to correlate survivin levels and recurrence. The probability for distant recurrence was determined for survivin levels in
human EAC tumor and adjacent squamous epithelial tissue. An increased survivin level in adjacent squamous epithelial tissue was determined to be a
risk factor for distant recurrence (p = 0.02).
doi:10.1371/journal.pone.0078343.g005
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Clinical implications of survivin overexpression
Thirty-seven EAC patients who underwent esophagectomy for
localized esophageal adenocarcinoma were included in the study
(Table 1). The samples comprised thirty males (81%) and seven
females (19%) with ages ranging from 44 to 90 years
(mean=62.76, sd = 10.94). Stage distribution of the study cohort
based on The American Joint Committee on Cancer (AJCC)
cancer staging confirmed 6 patients with stage I disease, 13 with
stage II and 18 patients with stage III disease (Table 2). Seven
patients received neo-adjuvant therapy and eighteen patients
received adjuvant chemotherapy after surgery. Two patients in the
neo-adjuvant group received concurrent chemo-radiation and the
majority of patients received platinum/fluorouracil based combi-
nation chemotherapy (Table 3). At a mean follow-up of 12.06
months, thirteen patients developed recurrence, 12 patients with
distant recurrence and 1 patient for which data was not reported.
Of the 12 patients with distant recurrence, 3 also had local
recurrence. Ten patients (77%) had died at the time of long-term
follow-up.
ROC analysis indicated that a threshold of greater than or equal
to 2.85 for mean survivin mRNA expression in CASE was
indicative of a heightened risk for distant recurrence with a
sensitivity of 0.77, specificity of 0.83, and an AUC of 0.73 (p,.05.
PPV=0.71, NPV=0.87) (Figure 5). Thus patients exhibiting
Figure 6. Kaplan-Meier survival curve based on high and low risk groups. Kaplan-Meier survival curves were generated for high and low risk
groups based on adjacent squamous epithelial survivin CASE expression. The high-risk group demonstrated an association with increased mortality,
although the correlation did not reach significance. Kaplan-Meier analysis for tumor survivin high and low risk groups yielded similar results (p = 0.11).
doi:10.1371/journal.pone.0078343.g006
Table 4. Cox Regression Survival Analysis.
Variable Omnibus Statistic X2 (Wald) p-value Odds Ratio
Odds Ratio 95%
Confidence Interval
Block G2 (6, N = 37) = 10.82 0.094
Alcohol 1.86 0.172 0.692 0.416–1.17
Smoking1 3.58 0.058 1.018 0.999–1.04
Age2 0.42 0.515 1.019 0.963–1.08
Barrett’s3 2.97 0.085 0.293 0.072–1.19
Risk: S4 2.28 0.131 2.55 0.758–8.55
Risk: T5 3.88 0.049 5.23 1.01–27.03
1In pack year.
2At time of esophagectomy.
3History of Barrett’s Esophagus.
4High risk group determined by adjacent squamous epithelial tissue mean Survivin levels.
5High risk group determined by tumor tissue mean Survivin levels.
doi:10.1371/journal.pone.0078343.t004
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mean survivin expression of 2.85 or greater in CASE were
classified into the high-risk group and those with expression levels
of less than 2.85 were categorized into the low risk group. Despite
a normal histologic appearance, survivin overexpression in CASE
proved to be an indicator of distant recurrence. Survivin
expression in tumor tissue did not correlate with recurrence.
Categorization into high and low risk groups using a threshold
tumor survivin expression of 3.66 did not predict recurrence
(p = 0.55) but did predict an increase in the odds of death from
EAC (described subsequently).
Kaplan-Meier survival curves were generated for high and low
risk groups based on CASE survivin expression. The high-risk
group demonstrated an association with increased mortality,
although the correlation did not reach significance (p = 0.12,
Figure 6). Kaplan-Meier analysis for tumor survivin high and low
risk groups yielded similar results (p = 0.11).
A Cox proportional hazards model was used to assess the
effectiveness of survivin level within both CASE and EAC tumor
tissue samples in predicting mortality. Other risk factors consid-
ered were age at time of esophagectomy, tobacco use (in packs per
years), alcohol consumption, and a history of Barrett’s esophagus
(Table 4). Smoking was associated with a higher death rate
(p = 0.06) with the odds of mortality being 1.018 greater for each
pack per year smoked. Survivin expression in tumor tissue was
associated with increased risk of death (p = 0.05). The probability
of a patient in the high-risk tumor survivin group experiencing
death was 5.23 times greater than that of a patient categorized in
the low risk group (p,.05).
Discussion
Studies have shown higher levels of survivin in metaplastic
columnar epithelium and dysplastic Barrett’s epithelium compared
to squamous tissue thus supporting the hypothesis that upregula-
tion of this gene is likely an early event preceding development of
adenocarcinoma [12]. Reports have also supported survivin as a
potential biomarker in esophageal squamous cell carcinoma [28]
but there is conflicting evidence regarding its prognostic role in
esophageal adenocarcinoma [29]. In a study by Rosato and
colleagues, survivin expression had no prognostic value for patients
with EAC. [9] The aim of the current study was to evaluate the
role of this anti-apoptotic gene in greater depth in esophageal
adenocarcinoma and CASE taking into consideration tumor
heterogeneity as well as expression of genetic changes prior to
histologic manifestation of tumor phenotype in adjacent epithe-
lium.
Analysis of human tissue using IHC, Western blot, and qRT-
PCR confirmed upregulation of survivin in EAC tumor tissue
compared to CASE. Our results established that increased survivin
expression in EAC tumor tissue is a risk factor for death with the
high-risk tumor survivin group being 5 fold more likely to die than
those categorized in the low-risk survivin group. It is possible that
the higher expression within the EAC tumor tissue may relate to
the aggressiveness of the tumor (i.e., worsening cellular dysregu-
lation), hence correlating with mortality. However, based on our
sample size, this study is likely underpowered and larger series of
patients would be needed to study these associations further.
Additionally expression of survivin in CASE was not altogether
absent, as would be expected for terminally differentiated normal
squamous epithelium [10,11]. Considering evidence demonstrat-
ing upregulation of this gene in pre-malignant metaplastic and
dysplastic columnar epithelium, our data suggest that survivin
overexpression may be an early genetic event occurring in
histologically normal appearing squamous epithelium prior to
development of metaplasia and transformation to adenocarcino-
ma. Though the mucosa adjacent to the tumor maintains
squamous differentiation, it harbors overexpression of this anti-
apoptotic gene that could be a potential driver of tumorigenesis.
Alternatively, it could be postulated that based on the correlation
with recurrence, survivin expression in CASE could be thought of
as the molecular equivalent of a positive margin and/or a
predictor of distant recurrence. If elevated survivin levels in CASE
represents molecular evidence that adjacent tissue is showing signs
of malignancy, the prognosis may be worse than that predicted by
the pTNM classification system. It could be postulated that the
fact that there was not an increase in mortality in patients with
elevated survivin levels in CASE could represents a type II error
secondary to the small sample size. Larger studies may help clarify
these associations.
The fact that survivin expression in tumor did not correlate with
recurrence could be from the fact that these patients had died
before recurrence could have been documented; this supposition is
supported by the fact that there were more patients with advanced
stage disease in the high-risk tumor expression group. Moreover,
as evidenced from prior studies, each tumor exhibits significant
heterogeneity with intra-tumor variations in somatic mutations,
allelic composition, tumor suppressor and oncogenic dysregulation
[30]. The predominance of multiple unique clones in sampled
tumor tissue may lead to inconsistent results when performing
molecular profiling of a given cancer. In the present study, fold
change in survivin mRNA was highly variable in tumor tissue in
comparison to CASE, and this may reflect tumor heterogeneity
and provide a potential explanation for the lack of correlation with
tumor recurrence. CASE demonstrated more consistent levels and
is perhaps a better substrate for evaluation of survivin as a
prognostic marker in patients with EAC. These data underscore
the need for a concerted effort to bank and analyze cancer-
adjacent histologically normal appearing tissue for molecular
profiling in EAC and perhaps other tumors.
Cell line analysis in the present study confirmed clear inhibition
of survivin through transfection with siRNA. Survivin was
effectively downregulated and cleaved caspase 3 was consumed
in the reaction leading to upregulation of cleaved PARP,
indicating that inhibition of survivin leads to activation of the
apoptotic pathway. As survivin is not expressed in normal tissue, it
is potentially an ideal target for novel agents [10,11]. Therefore,
effective inhibition through siRNA with downstream activation of
apoptosis supports the validity of future clinical trials in EAC
evaluating the effectiveness of a novel agent that uses siRNA or
other inhibitory avenues [10].
In conclusion the present study supports upregulation of
survivin as a potential early genetic change in EAC occurring in
normal appearing CASE. Survivin expression within EAC tissue
was a significant predictor of mortality while the expression level of
survivin in CASE was a more reliable predictor of tumor
recurrence. Additionally we also demonstrated that inhibition of
survivin in EAC cell lines leads to upregulation of apoptosis
supporting further evaluation of therapeutic strategies targeted to
this marker.
The limitations of the study include the small sample size and a
relatively shorter duration of follow up. Further studies with larger
sample sizes and longer follow up may help clarify some of the
associations noted in studies on survivin expression in EAC and
CASE. This would also help control for more factors impacting
recurrence and survival in patients with EAC.
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